2026 ICD-10-CM Diagnosis Code E85.3Secondary systemic amyloidosis
ICD-10-CM Codes›E00–E89›E70-E88›E85
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 50
- Chronic Condition
E85.3 is a billable ICD-10-CM diagnosis code for secondary systemic amyloidosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 10 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
For Medicare Advantage risk adjustment, E85.3 maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders) under the V28 model, adding a risk factor of about 0.648 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E85.3 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- AA amyloidosis
- Amyloid of familial Mediterranean fever
- Cardiac secondary systemic amyloidosis
- Cerebral amyloid angiopathy
- Cerebral secondary systemic amyloid angiopathy
- Complication of hemodialysis
- Glomerular disorder due to amyloidosis
- Glomerular disorder due to secondary systemic amyloidosis
- Hemodialysis-associated amyloidosis
- Hemodialysis-associated secondary amyloidosis of skin
- Long-term disorder of dialysis
- Secondary systemic amyloidosis
- Secondary systemic amyloidosis affecting skin
- Spondyloarthropathy due to hemodialysis-associated amyloidosis
- Systemic amyloidosis affecting skin
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Hemodialysis-associated amyloidosis
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Amyloid Neuropathies, Familial
inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (prealbumin); apolipoprotein a-i; and gelsolin.Cerebral Amyloid Angiopathy
a heterogeneous group of sporadic or familial disorders characterized by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges. clinical features include multiple, small lobar cerebral hemorrhage; cerebral ischemia (brain ischemia); and cerebral infarction. cerebral amyloid angiopathy is unrelated to generalized amyloidosis. amyloidogenic peptides in this condition are nearly always the same ones found in alzheimer disease. (from kumar: robbins and cotran: pathologic basis of disease, 7th ed., 2005)Cerebral Amyloid Angiopathy, Familial
a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.Cerebral Amyloid Angiopathy
a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.Cerebral Amyloid Angiopathy, APP-Related|HCHWAD|Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type
an autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the app gene, encoding amyloid-beta a4 protein. the deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. mutation(s) in the app gene may also cause autosomal dominant alzheimer disease 1.
Patient EducationClinical
Amyloidosis
Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E85.3 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E85.3Overview
What is the ICD-10 code for secondary systemic amyloidosis?
The ICD-10-CM code for secondary systemic amyloidosis is E85.3 (sometimes written as E853). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is E85.3 (Amyloidosis) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report secondary systemic amyloidosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does E85.3 group to?
When secondary systemic amyloidosis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.
Is E85.3 a CC or MCC?
CMS lists E85.3 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 10 closely related codes in its exclusion list.
What is the ICD-9 equivalent of E85.3?
Under the General Equivalence Mappings, secondary systemic amyloidosis converts to ICD-9-CM 277.39 (amyloidosis NEC). The mapping is approximate, so confirm the match fits the documentation.
What HCC is E85.3?
E85.3 (secondary systemic amyloidosis) maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders), commonly written as HCC 50, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does E85.3 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, E85.3 adds a risk adjustment factor of about 0.648 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.362 to 0.883 depending on the payment segment). HCC 50 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 50 category page.
